| Ytd | 3.75% | |
| 1y | 150.23% |
| Open | 32.22 | Prev Close | 32.23 | Low | 31.36 | High | 33.03 | Mkt Cap | 2.12B |
| Vol | 854.55K | Avg Vol | 793.69K | EPS | -3.34 | P/E | -9.84 | Forward P/E | -9.36 |
| Beta | 1.20 | Short Ratio | 14.65 | Inst. Own | 117.57% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 30.44 | 200-d Avg | 31.57 | 1yr Est | 47.00 |
STOK News
Dimensional Fund Advisors LP grew its position in Stoke Therapeutics, Inc. (NASDAQ: STOK) by 19.7% i
Stoke Therapeutics (NASDAQ: STOK) said its Phase III EMPEROR study of zorevunersen in patients with
Stoke Therapeutics Inc (NASDAQ:STOK) on Monday posted mixed results for the second quarter.
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.93 per share versus the Zacks C
Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen in patients with Dr
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
Goldman Sachs analyst Kevin Strang initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company
Stoke Therapeutics NASDAQ: STOK said its lead investigational therapy zorevunersen continued to show
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.79 per share versus the Zacks C
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85,
On Wednesday, 311 stocks hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
On Wednesday, 179 companies reached new 52-week lows.
Wednesday saw 59 companies set new 52-week lows.
Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average vo
On Tuesday, 951 companies hit new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Wednesday, 215 companies set new 52-week lows.
On Tuesday, 540 companies set new 52-week lows.
During Wednesday's trading, 435 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week
On Thursday, 105 stocks hit new 52-week lows.
On Friday morning, 155 companies achieved new lows for the year.
Before 10 a.m. ET on Wednesday, 375 companies hit new 52-week highs.
Tuesday's morning session saw 269 companies set new 52-week highs.
Friday's session saw 466 companies set new 52-week highs.